Korro Bio

aid: korro-bio
name: Korro Bio
description: 'Korro Bio, Inc. (Nasdaq: KRRO) is a Cambridge, Massachusetts clinical-stage biopharmaceutical company developing
  a new class of genetic medicines based on programmable RNA editing. Its proprietary OPERA (Oligonucleotide Promoted Editing
  of RNA) platform pairs data-driven oligonucleotide design and machine-learning optimization with linker chemistry and tissue-directed
  delivery to recruit the body''s own ADAR enzymes and make a precise, transient single-base edit to a native mRNA transcript
  — editing RNA rather than DNA so the change is tunable and reversible. The company was created and incubated by Atlas Venture
  with New Enterprise Associates in October 2019, raised a $91.5M Series A and a $116M Series B, and became public in 2023
  through a merger with Frequency Therapeutics alongside a $117M private placement. Its pipeline targets liver and central
  nervous system indications and includes KRRO-110 (the REWRITE Phase 1/2a study in alpha-1 antitrypsin deficiency), KRRO-111
  and KRRO-121, which holds EMA orphan drug designation for urea cycle disorders. Korro Bio sells therapeutics, not software:
  it operates no developer program, publishes no API, SDK or machine-readable specification, and maintains no public source-code
  organization.'
url: https://raw.githubusercontent.com/api-evangelist/korro-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pipeline
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
specificationVersion: '0.23'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- RNA Editing
- Genetic Medicine
- Drug Discovery
- Life Sciences
- Clinical Trials
- Rare Disease
- Research
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/korro-bio-domain-security.yml
- type: Website
  url: https://korrobio.com/
- type: InvestorRelations
  url: https://ir.korrobio.com/
- type: Careers
  url: https://korrobio.com/careers/
- type: TermsOfService
  url: https://korrobio.com/terms-conditions/
- type: PrivacyPolicy
  url: https://korrobio.com/privacy-policy/
- type: SecondaryMarket
  url: https://forgeglobal.com/korro-bio_stock/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: 'Korro Bio is a clinical-stage RNA-editing biopharmaceutical company (Nasdaq: KRRO) whose product is a drug pipeline,
    not software — there is no developer program, no API, no SDK on npm or PyPI and no GitHub organization; korrobio.com is
    a WordPress marketing site that answers every path, including the root, with a SiteGround robot-challenge (HTTP 202),
    and api./dev./docs./developer./mcp. are wildcard DNS to the same address rather than real hosts.'
  evidence:
  - url: https://korrobio.com/
    status: 202
  - url: https://korrobio.com/openapi.json
    status: 202
  - url: https://ir.korrobio.com/.well-known/security.txt
    status: 404
  - url: https://ir.korrobio.com/llms.txt
    status: 404
  - url: https://ir.korrobio.com/
    status: 200
  - url: https://api.github.com/search/users?q=korro+bio
    status: 200
  checked: '2026-08-23'